← Skye Bioscience, Inc. (SKYE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Skye Bioscience, Inc. (SKYE)
Pharmaceutical Preparations · market cap $7M · as of 2026-10-27
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Skye Bioscience (SKYE) is a 16-employee clinical-stage company with a ~$56M market cap (~35.4M shares at ~$1.57). Its pipeline in our database is nimacimab in obesity (Phase 2, listed twice) and SBI-100 ophthalmic emulsion in primary open angle glaucoma (Phase 2). Our data shows $8.1M of cash and a 4.2-month runway going into an estimated Phase 2 nimacimab catalyst on 2026-11-20, so the setup is a binary readout paired with a near-term financing question.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2026-11-20 (est.)Phase 2 · Nimacimab injectionimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Nimacimab injection | Phase 2 | Obesity |
| SBI-100 Ophthalmic Emulsion | Phase 2 | Primary Open Angle Glaucoma |
| Nimacimab | Phase 2 | Obesity |
Price & technical context
3-month
-70.5%
6-month
-80.5%
12-month
-88.2%
52-wk range
$1.45–$12.88
vs 50-day MA
-19.4%
vs 200-day MA
-70.7%
Realized vol
90.4%
Max drawdown
-96.2%
Daily closes through 2026-10-27. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SKYE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.